Journal
DIABETOLOGIA
Volume 46, Issue 2, Pages 288-290Publisher
SPRINGER-VERLAG
DOI: 10.1007/s00125-002-1008-1
Keywords
rosiglitazone; endothelial function; permeability; oedema; pulmonary; heart failure; thiazolidinedione
Categories
Ask authors/readers for more resources
Aims/hypothesis. Peripheral and pulmonary oedema has emerged as the most common drug-related side effect of rosiglitazone in clinical practice, but the underlying mechanisms are not clear. Fluid retention and changes in vascular tone could contribute to oedema formation, but the interpretation of clinical and in vivo studies is particularly difficult and the direct effects of thiazolidinediones on endothelial barrier function have not been previously reported. Methods. Human pulmonary artery endothelial cells were seeded and grown on 0.4 mum collagen-coated filters to form a tight monolayer (transendothelial electrical resistance 9-11 ohms.cm(-2) after 2-3 days). Transendothelial albumin flux (expressed as the percentage clearance of albumin relative to control) was measured using Evans blue-labelled albumin after exposure to rosiglitazone 1-100 mumol/l for 1 h to 48 h, and after removal of drug from the monolayer. Results. Incubation of pulmonary artery endothelial cells with rosiglitazone for 4 h produced immediate concentration-dependent increases in transendothelial albumin flux: e.g., relative to control (100%), 113%+/-13% (10 mumol/1), 215%+/-37% (10 mumol/l, p=0.01) and 461%+/-96% (100 mumol/l, p=0.002) (n=12). There was no effect after 1 h. The acute hyperpermeability response to rosiglitazone, maximal after 4 h, was fully reversible after washing the monolayer. After incubation for 24 to 48 It the effect of rosiglitazone on pulmonary endothelial permeability tended to subside: e.g., 210%+/-59% (24 h) for rosiglitazone 100 pmol/l (p=0.06). Conclusion/interpretation. Exposure to high-therapeutic concentrations of rosiglitazone causes a reversible fourfold increase in pulmonary endothelial permeability which could be clinically relevant especially at higher doses and at times of peak plasma drug concentration.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available